Royal Peptides
B2CRoyal Peptides is shown with a 5.8/10 consensus benchmark (5.4/10 blended) based on Finnrick 6.8/10 from 31 tests across 3 products and Peptide Critic 2.0/5 from 1 review; no country listed.
Profile aggregated from Peptigrity — attributed.
Weighted blend of independent signals — Finnrick safety grade, VialAudit blind-buy audit, and Peptigrity HPLC purity. PeptideBenchmark and the Peptigrity trust score are excluded to avoid double-counting. Attributed to its sources — not our verdict.
Independent test grades (0)
Per Finnrick (independent testing). Attributed — Finnrick's grades, not ours.
| Peptide | Grade | Score |
|---|
Independent HPLC tests (40)
Real third-party HPLC results for this vendor, aggregated from Peptigrity and attributed to the lab that ran each test.
| Peptide | HPLC purity | Lab | Date |
|---|---|---|---|
| Elamipretide | 99.38% | Janoshik Labs | — |
| Tirzepatide | 99.83% | Janoshik Labs | — |
| Elamipretide | 99.70% | Janoshik Labs | 2026-04-24 |
| Retatrutide | 99.78% | Janoshik Labs | 2026-04-01 |
| Retatrutide | 99.92% | Janoshik | 2026-03-30 |
| Tirzepatide | 99.88% | Janoshik Labs | 2026-02-06 |
| KPV | 99.27% |
Other independent ratings
Vendor-level scores from other independent aggregators, shown for cross-reference. Attributed — each source's score, not ours.